Author:
Friedman Lawrence M.,Furberg Curt D.,DeMets David L.,Reboussin David M.,Granger Christopher B.,Moore Thomas J.
Publisher
Springer International Publishing
Reference66 articles.
1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Safety Data Management: Definition and Standards for Expedited Reporting E2A, October 27, 1994.
2. United States Code, Code of Federal Regulations 21 CFR 314.80(a) Postmarketing reporting of adverse drug experiences. Definitions.
3. US General Accounting Office. FDA Drug Review: Postapproval Risks, 1976-85. Washington, DC: US General Accounting Office; April 26, 1990. GAO/PEMD-90-15.
4. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
5. Bresalier RS, Sandler RS, Quan H, et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献